Oragenics Inc. (NYSE American: OGEN) announced that all three sites in its Australian Phase IIa clinical trial of ONP-002 for mild traumatic brain injury (concussion) are now active and enrolling participants, following the activation of Royal Adelaide Hospital. The company reported that no serious adverse events have been observed in dosed participants to date, and it continues to target a Phase IIa data readout in the fourth quarter of 2026.
In addition to the trial progress, Oragenics disclosed that it submitted a Type B meeting request to the U.S. Food and Drug Administration on June 26 to obtain guidance on its planned U.S. clinical development program for ONP-002. The company stated that the meeting supports its goal of submitting an Investigational New Drug application in the fourth quarter of 2026. This regulatory engagement is a critical step toward advancing the candidate in the U.S. market.
ONP-002 is a potential first-in-class treatment for concussion and mild traumatic brain injury, delivered through Oragenics' proprietary intranasal delivery technology. The company believes this platform has broad applications across neurological conditions, including Parkinson's disease, Alzheimer's disease, PTSD, and anxiety disorders.
The activation of all Australian trial sites marks a significant milestone for Oragenics, as it accelerates enrollment for the Phase IIa study. The company's ability to initiate and progress clinical trials in Australia, while simultaneously engaging with the FDA, demonstrates a strategic approach to global drug development. The absence of serious adverse events in the initial dosing provides early safety data that supports further investigation.
Investors and stakeholders can monitor further updates through the company's newsroom at https://ibn.fm/OGEN. The full press release is available at https://ibn.fm/Yye2E.
Oragenics, a clinical-stage biotechnology company, is focused on developing brain-targeted therapeutics via intranasal delivery. With ONP-002 advancing through clinical trials, the company aims to address significant unmet medical needs in neurological care. The upcoming Phase IIa data readout and potential FDA guidance will be pivotal in shaping the future development path for this promising therapy.
